ISAKOS Congress Call for Abstracts

ACCME Standards for Integrity and Independence in Accredited Continuing Education require providers to mitigate relevant financial relationships to prevent commercial bias and disclose the presence or absence of all relevant financial relationships to learners prior to the activity. According to Standard 3.2 of the ACCME Standards for Integrity and Independence in Accredited Continuing Education, “Owners and employees of ineligible companies must be excluded from controlling content or participating as planners or faculty in accredited education”. The Presenting Author of any accepted abstract /poster cannot be employed by an ACCME- defined ineligible company*. Employees of ineligible companies are prohibited from having any role in the planning or implementation of CME activities related to the ineligible company’s business lines or products.

*An ineligible company (formerly called a commercial interest) is one whose primary business is producing, marketing, re-selling, or distributing health care products used by, on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.

You may be required to edit your submission if it is found to be noncompliant with these standards:

  • ACCME and HIPPA Compliance- All individually identifiable health information regarding a client or patient must be sufficiently edited or modified to ensure HIPPA compliance.
  • Presentations must give a balanced view of therapeutic options. All recommendations for patient care must be based on current science, evidence, and clinical reasoning.
  • New and evolving topics must be clearly identified in the presentation slides.
  • Presentations must be free of commercial bias for or against any company, product, drug, or device.
  • Educational materials (abstracts, presentations, videos, and photos) must not include:
    • Ineligible companies’ corporate or product logos.
    • Company, product, drug, or device brand/trade names. (generic names should be used)
    • If brand/trade names are listed, there MUST be at least two (2) other names listed to avoid the perception of bias.
    • If only one is listed, it must be proven to be the one and only best product, device, and/or drug available.
  • All logos or brand names visible in photos or videos must be completely covered.
  • All abstracts will be reviewed for compliance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education.

Abstract Submissions Open March 10, 2026 | Deadline August 4, 2026

Don’t miss your chance to submit Abstracts for the 2027 ISAKOS Congress being offered live in Sydney, Australia, May 30-June 2, 2027.

Abstracts will be considered for in-person podium presentations and electronic and in-person posters. In addition, exceptional abstracts will be considered for several ISAKOS Awards for outstanding clinical or laboratory research. These awards will be presented at Congress in Sydney.

Submit an Abstract

Instructions for submitting an abstract:

  • Log-in using the presenting author’s email and password for ISAKOS. If a record does not exist for the presenting author, you will be prompted to create a new record.
  • Complete contact information for the presenting and other authors, including the institution of research. It is helpful to have the ISAKOS ID numbers for as many authors as possible. You may email isakos@isakos.com to obtain an author’s ISAKOS ID number—please do not make duplicate records.
  • Complete the American Food and Drug Administration (FDA) Statement and Copyright License Agreement on behalf of all authors.
  • Provide the abstract title in capital letters for publishing, e.g., THE SCIENCE OF ORTHOPAEDIC SURGERY
  • Enter the plain abstract text in the provided text box. Please note, graphics and tables are not accepted. There is a maximum of 500 words for the abstract summary.

Once the abstract is submitted by the presenting author, any other authors will be notified to complete their disclosures with ISAKOS.
Abstracts will not be reviewed until ALL author disclosures are completed.

Abstract Review
Following the submission deadline, all abstracts are blindly reviewed by committees of qualified orthopaedic surgeons.

Notification of Results
The presenting author will receive a letter of acceptance or rejection via email for the abstract by December 1, 2026.

Abstract Submission Guidelines

Author warranty: Persons submitting an abstract to ISAKOS do so with the understanding that they and all the authors listed on the abstract will abide by the guidelines, conditions, deadlines, policies, and decisions of the ISAKOS Board of Directors and Congress Program Committee.

  1. The deadline for abstract submission is August 4, 2026, at 11:59 pm Pacific Daylight Time. Abstracts will not be accepted after that time.
  2. Abstracts must be submitted from the ISAKOS account of the Presenting Author.
  3. Authors do not have to be ISAKOS members to submit an abstract.
  4. There is no limit to the number of abstracts that can be submitted for consideration; however, each presenting author will be limited to no more than two paper presentations during the ISAKOS Congress.
  5. If the abstract is accepted for podium presentation, the presenting author must speak in English and be prepared to answer questions from the audience in English.
  6. All presenters, co-authors, and faculty members who attend the Congress are expected to register for the meeting and pay all registration and travel costs. No exceptions are made. If attendance is dependent on outside funding, please secure financial assistance before submitting an abstract.
  7. Abstracts are only accepted for consideration via the online abstract application form. Abstracts submitted in any other fashion will not be considered.
  8. Abstracts must be original and must not have been published or presented at any other meeting prior to the ISAKOS 2027 Congress.
  9. The ISAKOS Program Committee will make final decisions on the abstract presentation format.
  10. Presenting authors and co-authors must complete a Financial Disclosure Statement, as well as an American Food and Drug Administration statement within the abstract application.  Although ISAKOS is an international society, it receives continuing medical education accreditation and is planned and implemented in accord with the essential areas and policies of the Accreditation Council for Continuing Medical Education (ACCME).
  11. Presenting authors must complete a Copyright License Agreement so the chosen abstracts can be published by ISAKOS. Channels may include the ISAKOS and Journal of ISAKOS websites.
  12. Abstract text is a maximum of 500 words.

Abstract Grading Criteria
Abstracts are graded on a scale from 0.0 to 12.0 (12.0 being the best) based on the following:

  • Scientific Merit (0-6, with 6 points max)
    • Is the problem clearly stated?
    • Are the statistics sound?
    • Are there adequate numbers of subjects?
    • How is the methodology? {are there controls?, is this prospective vs. retrospective?}
    • Is the abstract clear / well written and are the results clear?
    • Are the conclusions supported by the results?
  • Originality of Project (0-2 points)
  • Clinical Usefulness (0-2 points)
  • Level of Interest to ISAKOS Members (0-2 points)

Learn more about the abstract categories and ISAKOS awards: 

View Abstract Primary Categories
View Abstract Awards